ACE2 News and Research

RSS

Study demonstrates long-term neuropsychological consequences following SARS-CoV-2 infection

The study, published in the pre-print server medRxiv, demonstrates the presence of long-lasting neuropsychological sequelae after COVID-19, regardless of the respiratory disease's severity.

2 Mar 2021

Early antibody response predicts COVID-19 outcome

To address this gap, researchers from the U.S. evaluated the timing of antibody production against SARS-CoV-2 in hospitalized patients. They used a highly sensitive multiplexed bead-based immunoassay that allows for early detection of anti-SARS-CoV-2 antibodies. The study is published on the preprint server medRxiv.

2 Mar 2021

Concerning mutation in New York SARS-CoV-2 should be monitored, warn researchers

Researchers at the New York State Department of Health in the United States have said concerning mutations within the B.1.526 lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has recently become prevalent in New York State warrant further monitoring.

2 Mar 2021

New nanoparticle-delivered COVID-19 vaccine candidate shows efficacy in ferret model

Researchers from Cleveland Clinic's Global Center for Pathogen Research & Human Health have developed a promising new COVID-19 vaccine candidate that utilizes nanotechnology and has shown strong efficacy in preclinical disease models.

2 Mar 2021

Could small synthetic antigen proteins be diagnostic tools for SARS-CoV-2?

Researchers have developed small proteins from sequences in SARS-CoV-2's RBD that bind to ACE2. These were as effective in binding to neutralizing antibodies as larger RBD proteins.

2 Mar 2021

Evonik partners with BioNTech to manufacture lipids for COVID-19 vaccine

Caused by SARS-CoV-2, the coronavirus disease 2019 (COVID-19) pandemic continues to spread across the globe.

From Evonik 2 Mar 2021

SARS-CoV-2 UK variant shows low virulence and high shedding in hamster model

A new study compares the pathogenicity and infectiousness of one such variant, the VOC 202012/01 (B.1.1.7 lineage) from the United Kingdom, with the globally dominant D614G mutation-carrying strains.

2 Mar 2021

Study shows asthma mediator IL-13 prevents SARS-CoV-2 infection

In a paper published on the bioRxiv preprint server, researchers reported the results on whether IL-13 expression in asthma patients reduces their susceptibility to SARS-CoV-2 infection.

1 Mar 2021

Scientists establish infection models for SARS-CoV-2 UK & South African variants

New research suggests Syrian golden hamsters could be a potentially useful preclinical model for testing vaccine immunity against the acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.17 and B.1.351 variant.

1 Mar 2021

Comparative analysis of SARS-CoV-2 antivirals leads to new potential treatment for COVID-19

Scientists compared the in vitro efficacy and cytotoxicity profiles of PF-00835231 and remdesivir in two human model systems for SARS-CoV-2 infection.

1 Mar 2021

Researchers evaluate surrogate large-scale SARS-CoV-2 serosurveillance test

A team of international scientists has recently evaluated a surrogate virus neutralization test for severe acute respiratory coronavirus 2 (SARS-CoV-2) and observed that it is highly efficacious for detecting anti-SARS-CoV-2 neutralizing antibodies in serum samples. According to the scientists, the test can be effectively used for population-level serosurveillance and evaluation of vaccine efficacy. The study is currently available on the medRxiv* preprint server.

1 Mar 2021

New paper discusses how smoking may affect risk for COVID-19

A new paper published online in the Annals of the American Thoracic Society discusses how smoking may affect risk for COVID-19 and the types of research that are needed to better understand the link between smoking and COVID-19 risk.

1 Mar 2021

Researchers develop new tool for predicting the effects of SARS-CoV-2 missense variants

A new study by a team of researchers in the UK and US describes the use of a computational tool that generates all possible single amino acid substitutions in SARS-CoV-2 and predicts their effects.

26 Feb 2021

Inhalable nanobody shows potent anti-SARS-CoV-2 activity in vivo

Researchers have developed a stable and ultrapotent homotrimeric Pittsburgh inhalable Nanobody 21 (PiN-21) against SARS-CoV-2 infection in Syrian hamsters. They demonstrated the high therapeutic efficacy of this homotrimeric Nb, leveraging both intranasal and aerosol delivery.

26 Feb 2021

Study explains the evolution of SARS-CoV-2 virus

As COVID-19 sweeps the world, related viruses quietly circulate among wild animals. A new study shows how SARS-CoV-2, the virus that causes COVID-19, and SARS-CoV-1, which caused the 2003 SARS outbreak, are related to each other.

26 Feb 2021

Pre-existing cross-reactive HCoV antibodies could protect against SARS-CoV-2

A team of researchers from Spain and Canada recently characterized the antibody kinetics and neutralization capacity at 4 cross-sectional surveys between March and October 2020 and determined the seroprevalence in the same cohort of healthcare workers.

25 Feb 2021

Neuroinvasiveness of SARS-CoV-2 shown by viral RNA and inflammation in the brain

A new study describes the results of a macaque study that showed the development of neurological features of inflammation, following infection by SARS-CoV-2.

25 Feb 2021

Study explores individual differences of SARS-CoV-2 infection in ACE2-expressing stem cells

The clinical phenotype of COVID-19, caused by SARS-CoV-2, is remarkable for its wide range of severity among individual patients. Genetic variations are known to mediate part of these differences. To examine these differences, researchers in a new study used human induced pluripotent stem cells (iPSCs) from different genetically diverse individuals. These cells are used to model genetic disease since they contain the donor’s genetic information. Researchers use a panel of iPSCs from over 500 individuals. The researchers preferred undifferentiated iPSCs to reduce the time required to differentiate them, especially since infection is not always reliable.

25 Feb 2021

High expression of ACE2 receptors in developing ovaries increases SARS-CoV-2 risk

A team of scientists from China collaborated to find if SARS-CoV-2 could also infect the ovary at different developmental stages.

25 Feb 2021

Lab study of South African SARS-CoV-2 variant and Moderna vaccine: reduced neutralization, but still protective

Researchers from the US recently compared antibody binding and viral neutralization against 2 SARS-CoV-2 variants that emerged in different parts of the world. The researchers used sera from spike mRNA vaccinated and naturally infected individuals against a circulating B.1 variant and the emerging B.1.351 variant. The study is published on the preprint server bioRxiv.

24 Feb 2021

ACE2 News and Research

Study demonstrates long-term neuropsychological consequences following SARS-CoV-2 infection

Early antibody response predicts COVID-19 outcome

Concerning mutation in New York SARS-CoV-2 should be monitored, warn researchers

New nanoparticle-delivered COVID-19 vaccine candidate shows efficacy in ferret model

Could small synthetic antigen proteins be diagnostic tools for SARS-CoV-2?

Evonik partners with BioNTech to manufacture lipids for COVID-19 vaccine

SARS-CoV-2 UK variant shows low virulence and high shedding in hamster model

Study shows asthma mediator IL-13 prevents SARS-CoV-2 infection

Scientists establish infection models for SARS-CoV-2 UK & South African variants

Comparative analysis of SARS-CoV-2 antivirals leads to new potential treatment for COVID-19

Researchers evaluate surrogate large-scale SARS-CoV-2 serosurveillance test

New paper discusses how smoking may affect risk for COVID-19

Researchers develop new tool for predicting the effects of SARS-CoV-2 missense variants

Inhalable nanobody shows potent anti-SARS-CoV-2 activity in vivo

Study explains the evolution of SARS-CoV-2 virus

Pre-existing cross-reactive HCoV antibodies could protect against SARS-CoV-2

Neuroinvasiveness of SARS-CoV-2 shown by viral RNA and inflammation in the brain

Study explores individual differences of SARS-CoV-2 infection in ACE2-expressing stem cells

High expression of ACE2 receptors in developing ovaries increases SARS-CoV-2 risk

Lab study of South African SARS-CoV-2 variant and Moderna vaccine: reduced neutralization, but still protective

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News